Anixa Biosciences Inc. has announced the execution of a data transfer agreement with Cleveland Clinic, marking a key step in the process of transferring the investigational new drug (IND) sponsorship for its breast cancer vaccine clinical trial. This agreement will facilitate the transfer of all relevant Phase 1 clinical trial data to Anixa, as the company prepares to assume full sponsorship of the IND and advance the vaccine to a Phase 2 clinical trial. Enrollment for the Phase 1 trial has been completed, with encouraging immune response data observed. The final Phase 1 data will be presented by Cleveland Clinic at the San Antonio Breast Cancer Symposium on December 11. The breast cancer vaccine, developed in collaboration with Cleveland Clinic, targets α-lactalbumin, a protein associated with lactation that is also present in many breast cancers.